目的：分析依达拉奉联合马来酸桂哌齐特治疗急性脑梗死的效果。方法将我院收治的急性脑梗死患者147例分为两组，治疗组74例给予依达拉奉联合马来酸桂哌齐特治疗，对照组73例给予血塞通治疗。结果治疗组治疗后1周、2周 NIHSS 评分（13.86±3.58）分、（7.15±2.16)）分，低于对照组（19.37±7.55）分、（13.20±5.34）分，其总有效率97.30%，高于对照组75.34%，两组治疗效果对比，差异有统计学意义（P ＜0.05）。结论依达拉奉联合马来酸桂哌齐特治疗急性脑梗死，可降低 NIHSS 评分，提高临床疗效。%Objective Analysis of edaravone combined with cinepazide maleate in the treatment of acute cerebral infarction effect. Methods The 147 cases of patients with acute cerebral infarction were treated in our hospital were divided into two groups, treatment group 74 cases was treated with edaravone combined with cinepazide maleate in treatment, 73 patients in the control group treated with xuesaitong in the treatment. Results After treatment, 1 week, 2 weeks NIHSS score (13.86±3.58), (7.15±2.16), lower than that of the control group (19.37±7.55), (13.20±5.34), the total efficiency of 97.30%, higher than that of the control group 75.34%, comparing the therapeutic effect of two groups, the difference is statistically significant (P<0.05). Conclusion Edaravone combined with cinepazide maleate in the treatment of acute cerebral infarction can reduce NIHSS score, improve the clinical efficacy.
展开▼
